Today: 9 June 2026
Bolsa de Comercio de Buenos Aires Last Week: Merval Rebounds, but Oil Shock and Inflation Loom

Bolsa de Comercio de Buenos Aires Last Week: Merval Rebounds, but Oil Shock and Inflation Loom

BUENOS AIRES, March 7, 2026, 06:42 ART

Buenos Aires shares bounced back Friday, sending the S&P Merval 2.15% higher to end at 2,626,114.83 points. Still, comparing the Feb. 27 and March 6 closes, the index wrapped up the week roughly 0.6% lower than its opening level.

This is coming to a head fast—traders don’t have room to relax. Argentina’s February CPI lands March 12. The central bank’s REM survey, out March 5, pushed the consensus for February inflation up to 2.7%, compared with the previous reading. Core inflation? Now at 2.5%. The oil shock just stirs the pot further, clouding the inflation picture.

Aluar, Ternium Argentina, and YPF paced Friday’s bounce, but Banco Macro and Grupo Financiero Galicia couldn’t keep up. Bonds told a different story: sovereign dollar debt slipped roughly 0.9% on the session, and the risk premium on Argentine paper climbed to 575 basis points. In other words, cash stayed picky—no broad rush into Argentina.

This week, the mood was sour. Argentina landed near the bottom of emerging-market equity fund performers for the month, LSEG Lipper data showed, as reported by Reuters. The MSCI emerging markets index dropped over 6% during the week. Oil prices, meanwhile, jumped nearly 30% within days as the Middle East conflict rattled shipping routes and energy supplies.

Grupo SBS chief economist Juan Manuel Franco described the environment as “highly turbulent,” pointing to a surge in energy prices and a drop in risk assets as fighting intensified. Economist Gustavo Ber noted that investors were focused on signals about the conflict’s duration, watching closely to see if oil prices would ease enough for Wall Street to catch a breather. El Cronista

Strip away the headlines and the local narrative is still in play. Congress signed off on Javier Milei’s labor reform last Friday. This week, the president argued Argentina needs lower taxes and more changes to its institutions—a reform agenda some corners of the market continue to see as a positive.

Oil-tied stocks aren’t just drifting. Argentina’s energy trade could swing to a surplus of $8.5 billion to $10 billion in 2026 with Vaca Muerta driving up exports—a number that goes a long way toward understanding why YPF and other energy shares outperformed banks heading into the weekend.

It’s a trend cropping up all over the region. Brazil’s Petrobras flagged this week that the fresh oil surge might be enough to boost cash flow for possible extra dividends, management quick to note the war’s uncertainty. That’s kept LatAm energy shares on firmer ground, even while risk assets elsewhere look shaky.

The margin here is narrow. According to former Energy Secretary Daniel Montamat, a sustained crude rally could drive Argentine fuel prices up by as much as 5% to 7%. He estimates fuel’s direct share of the CPI basket at about 2% to 4%. Barclays, for its part, sees Brent pushing toward $120 a barrel if the conflict continues.

Next week shapes up as a pivotal stretch for the Bolsa de Comercio de Buenos Aires. The central bank snapped up $1.555 billion in February, and Franco flagged that reserve buildup and peso interest rates remain squarely in the spotlight for investors. With the CPI data set for March 12 and inflation expectations ticking upward, Friday’s bounce might not have much time to make its case.

Stock Market Today

  • Pro Portfolio Adds Broadcom and Netflix Shares, Upgrades Broadcom Rating
    June 9, 2026, 10:19 AM EDT. The Pro Portfolio is buying 80 shares of Broadcom (AVGO) at around $405, increasing its holdings to 512 shares (3.4% of the portfolio). It is also purchasing 372 shares of Netflix (NFLX) near $82.35, increasing its stake to 2,107 shares (2.85%). Broadcom's AI chip forecast for H2 2026 is viewed as conservative following a $35 billion private credit deal involving Apollo and Blackstone. The rating for Broadcom is upgraded to One, with a checkpoint price of $330 maintained. Netflix's shares are seen as undervalued despite recent declines, supported by a $25 billion buyback and rising U.S. viewership. Netflix's ad business shows growth potential, reaching 250 million monthly active viewers, reinforcing optimism amidst concerns over consumer spending.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Nvidia halts China H200 chip production and shifts TSMC capacity to Vera Rubin, report says
Previous Story

Nvidia halts China H200 chip production and shifts TSMC capacity to Vera Rubin, report says

Micron Technology stock week ahead: 6.7% slide puts March 18 earnings and AI demand in focus
Next Story

Micron Technology stock week ahead: 6.7% slide puts March 18 earnings and AI demand in focus

Go toTop